Keyphrases
Tumor-infiltrating Lymphocytes
83%
Tumor-infiltrating Lymphocyte Therapy
66%
Adoptive Cell Therapy
37%
LTX-315
33%
Ipilimumab
33%
Advanced Melanoma
33%
Tumor-specific T Cells
33%
Metastatic Soft Tissue Sarcoma
33%
Confidence Interval
25%
Phase II Trial
12%
Systemic Immune Response
11%
Logistic Problem
8%
Positive Phase
8%
Treatment Modalities
8%
Effective Treatment
8%
Histological Subtypes
8%
Solid Tumors
8%
Safe Treatment
8%
Metastatic Melanoma
8%
Economic Challenges
8%
Regulatory Approval
8%
Progression-free Survival
7%
Chemotherapy
7%
Oncolytic Peptide
5%
Local Immune Response
5%
Disease Progression
5%
Clinical Activity
5%
Intratumoral Injection
5%
Clinical Response
5%
Stable Disease
5%
Heavily Pretreated Patients
5%
T-cell Reactivity
5%
Autoreactive T Cells
5%
T Cell Clone
5%
Treatment Protocol
5%
Neoantigen
5%
Sarcoma
5%
Progressive Disease
5%
In Silico
5%
Medicine and Dentistry
Tumor Infiltrating Lymphocyte
100%
Cell Therapy
36%
T Cell
33%
Ipilimumab
33%
Specific Tumor
33%
Soft Tissue Sarcoma
33%
Hope
33%
Nodular Melanoma
33%
Disease
12%
Immune Response
9%
Progression Free Survival
9%
Solid Malignant Neoplasm
5%
Metastatic Melanoma
5%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
66%
Melanoma
33%
Ipilimumab
33%
Progression Free Survival
9%
Chemotherapy
6%
Metastatic Melanoma
5%
Solid Malignant Neoplasm
5%
